Cargando…

Lipid-lowering therapies and achievement of LDL-cholesterol targets

Detalles Bibliográficos
Autores principales:	Rizzo, Manfredi, Banach, Maciej, Montalto, Giuseppe, Mikhailidis, Dimitri P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460494/ https://www.ncbi.nlm.nih.gov/pubmed/23056067 http://dx.doi.org/10.5114/aoms.2012.30281

Ejemplares similares

The effects of statins on blood pressure: current knowledge and future perspectives
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
por: Katsiki, Niki, et al.
Publicado: (2020)

Statin treatment in the elderly: how much do we know?
por: Rizzo, Manfredi, et al.
Publicado: (2013)

Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?
por: Anagnostis, Panagiotis, et al.
Publicado: (2023)

Are we getting to lipid targets in real life?
por: Katsiki, Niki, et al.
Publicado: (2010)

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy
por: Masana, Lluís, et al.
Publicado: (2020)

Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level
por: Fendler, Wojciech, et al.
Publicado: (2014)

Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988)
por: Banach, Maciej, et al.
Publicado: (2022)

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
por: Karalis, Dean G., et al.
Publicado: (2012)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target
por: Hoenig, Michel R
Publicado: (2008)

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches
por: Nikolic, Dragana, et al.
Publicado: (2013)

Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”)
por: Makhmudova, Umidakhon, et al.
Publicado: (2023)

Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate
por: Hobbs, FD Richard, et al.
Publicado: (2016)

The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up
por: Bielecka-Dabrowa, Agata, et al.
Publicado: (2013)

Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions
por: Zhang, Shuang, et al.
Publicado: (2022)

Can we achieve ESC 2019 guidelines LDL-cholesterol target in Tunisia?
por: Ibn Elhadj, Zied, et al.
Publicado: (2022)

LDL-C: lower is better for longer—even at low risk
por: Penson, Peter E., et al.
Publicado: (2020)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

Targeting LDL Cholesterol With LNA
por: Krieg, Arthur M
Publicado: (2012)

Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
por: Sosnowska, Bożena, et al.
Publicado: (2022)

A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control
por: Turner, Barbara J, et al.
Publicado: (2011)

Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial
por: Berthold, Heiner K., et al.
Publicado: (2014)

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study
por: Toth, Peter P., et al.
Publicado: (2016)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease
por: Masuda, Daisaku, et al.
Publicado: (2022)

Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
por: Telci Caklili, Ozge, et al.
Publicado: (2023)

CETP inhibition in the REVEAL trial: could we aim higher?
por: Sahebkar, Amirhossein, et al.
Publicado: (2020)

More Good News on Statins and COVID-19
por: Katsiki, Niki, et al.
Publicado: (2021)

Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!
por: Katsiki, Niki, et al.
Publicado: (2019)

Complications of Diabetes 2017
por: Papatheodorou, Konstantinos, et al.
Publicado: (2018)

2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy
por: Banach, Maciej, et al.
Publicado: (2022)

Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy
por: Diamond, David M, et al.
Publicado: (2023)

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
por: Yun, Yeo-Min
Publicado: (2023)

Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration
por: Snaterse, Marjolein, et al.
Publicado: (2017)

Fat-to-Muscle Ratios and the Non-Achievement of LDL Cholesterol Targets: Analysis of the Korean Genome and Epidemiology Study
por: Cho, A-Ra, et al.
Publicado: (2021)

Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes
por: Morieri, Mario Luca, et al.
Publicado: (2022)

Questioning the importance of LDL cholesterol: don’t throw the baby out with the bathwater!
por: Raal, FJ
Publicado: (2008)

Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?: Results from the DA VINCI study
por: Siostrzonek, Peter, et al.
Publicado: (2021)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_844hkvkmrmf6o4tfqlteofkqjg